BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 16132577)

  • 1. Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow.
    Cabioglu N; Sahin A; Doucet M; Yavuz E; Igci A; O Yildirim E; Aktas E; Bilgic S; Kiran B; Deniz G; Price JE
    Clin Exp Metastasis; 2005; 22(1):39-46. PubMed ID: 16132577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer.
    Cabioglu N; Yazici MS; Arun B; Broglio KR; Hortobagyi GN; Price JE; Sahin A
    Clin Cancer Res; 2005 Aug; 11(16):5686-93. PubMed ID: 16115904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer.
    Kaifi JT; Yekebas EF; Schurr P; Obonyo D; Wachowiak R; Busch P; Heinecke A; Pantel K; Izbicki JR
    J Natl Cancer Inst; 2005 Dec; 97(24):1840-7. PubMed ID: 16368946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative analysis between the HER2 status in primary breast cancer tissue and the detection of isolated tumor cells in the bone marrow.
    Schindlbeck C; Janni W; Shabani N; Rack B; Gerber B; Schmitt M; Harbeck N; Sommer H; Braun S; Friese K
    Breast Cancer Res Treat; 2004 Sep; 87(1):65-74. PubMed ID: 15377852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distribution of CXCR4 and γ-catenin expression pattern in breast cancer subtypes and their relationship to axillary nodal involvement.
    Sivrikoz ON; Doganay L; Sivrikoz UK; Karaarslan S; Sanal SM
    Pol J Pathol; 2013 Dec; 64(4):253-9. PubMed ID: 24375039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolated tumor cells in the bone marrow (ITC-BM) of breast cancer patients before and after anthracyclin based therapy: influenced by the HER2- and Topoisomerase IIalpha-status of the primary tumor?
    Schindlbeck C; Janni W; Shabani N; Kornmeier A; Rack B; Rjosk D; Gerber B; Braun S; Sommer H; Friese K
    J Cancer Res Clin Oncol; 2005 Aug; 131(8):539-46. PubMed ID: 15887027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Basal Protein Expression Is Associated With Worse Outcome and Trastuzamab Resistance in HER2+ Invasive Breast Cancer.
    Chung A; Choi M; Han BC; Bose S; Zhang X; Medina-Kauwe L; Sims J; Murali R; Taguiam M; Varda M; Schiff R; Giuliano A; Cui X
    Clin Breast Cancer; 2015 Dec; 15(6):448-457.e2. PubMed ID: 26248960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Significance of expression of stromal cell derived factor 1 and CXCR4 in invasive breast cancer].
    Liu FF; Wei J; Lang RG; Fan Y; Cui LF; Gu F; Fu L
    Zhonghua Bing Li Xue Za Zhi; 2008 Aug; 37(8):529-35. PubMed ID: 19094464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Her2 expression on disseminated tumor cells from bone marrow of breast cancer patients.
    Becker S; Becker-Pergola G; Fehm T; Wallwiener D; Solomayer EF
    Anticancer Res; 2005; 25(3B):2171-5. PubMed ID: 16158960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative microvessel area of the primary tumour, and not lymph node status, predicts the presence of bone marrow micrometastases detected by reverse transcriptase polymerase chain reaction in patients with clinically non-metastatic breast cancer.
    Benoy IH; Salgado R; Elst H; Van Dam P; Weyler J; Van Marck E; Scharpé S; Vermeulen PB; Dirix LY
    Breast Cancer Res; 2005; 7(2):R210-9. PubMed ID: 15743502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunomagnetic enrichment of disseminated tumor cells in bone marrow and blood of breast cancer patients by the Thomsen-Friedenreich-Antigen.
    Schindlbeck C; Stellwagen J; Jeschke U; Karsten U; Rack B; Janni W; Jückstock J; Tulusan A; Sommer H; Friese K
    Clin Exp Metastasis; 2008; 25(3):233-40. PubMed ID: 18185913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study.
    Salvucci O; Bouchard A; Baccarelli A; Deschênes J; Sauter G; Simon R; Bianchi R; Basik M
    Breast Cancer Res Treat; 2006 Jun; 97(3):275-83. PubMed ID: 16344916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunomagnetic enrichment and detection of isolated tumor cells in bone marrow of patients with epithelial malignancies.
    Weihrauch MR; Skibowski E; Draube A; Geller A; Tesch H; Diehl V; Bohlen H
    Clin Exp Metastasis; 2002; 19(7):617-21. PubMed ID: 12498391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR.
    Hicks DG; Short SM; Prescott NL; Tarr SM; Coleman KA; Yoder BJ; Crowe JP; Choueiri TK; Dawson AE; Budd GT; Tubbs RR; Casey G; Weil RJ
    Am J Surg Pathol; 2006 Sep; 30(9):1097-104. PubMed ID: 16931954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow.
    Braun S; Hepp F; Kentenich CR; Janni W; Pantel K; Riethmüller G; Willgeroth F; Sommer HL
    Clin Cancer Res; 1999 Dec; 5(12):3999-4004. PubMed ID: 10632331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trastuzumab clears HER2/neu-positive isolated tumor cells from bone marrow in primary breast cancer patients.
    Rack B; Jückstock J; Günthner-Biller M; Andergassen U; Neugebauer J; Hepp P; Schoberth A; Mayr D; Zwingers T; Schindlbeck C; Friese K; Janni W
    Arch Gynecol Obstet; 2012 Feb; 285(2):485-92. PubMed ID: 21717141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of RANK, RANKL, OPG, and CXCR4 tissue markers in predicting bone metastases in breast cancer patients.
    Ibrahim T; Sacanna E; Gaudio M; Mercatali L; Scarpi E; Zoli W; Serra P; Ricci R; Serra L; Kang Y; Amadori D
    Clin Breast Cancer; 2011 Dec; 11(6):369-75. PubMed ID: 21764390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterisation of disseminated tumor cells in the bone marrow of breast cancer patients by the Thomsen-Friedenreich tumor antigen.
    Schindlbeck C; Jeschke U; Schulze S; Karsten U; Janni W; Rack B; Sommer H; Friese K
    Histochem Cell Biol; 2005 Jun; 123(6):631-7. PubMed ID: 15889266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A summary of two clinical studies on tumor cell dissemination in primary and metastatic breast cancer: methods, prognostic significance and implication for alternative treatment protocols (Review).
    Kasimir-Bauer S; Oberhoff C; Schindler AE; Seeber S
    Int J Oncol; 2002 May; 20(5):1027-34. PubMed ID: 11956600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.